Standard Contracts
UNDERWRITING AGREEMENT Edgewise Therapeutics, Inc. 21,818,182 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • January 19th, 2024 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 19th, 2024 Company Industry JurisdictionEdgewise Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 21,818,182 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Shares”). The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
EDGEWISE THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • March 5th, 2021 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 5th, 2021 Company Industry JurisdictionThis Indemnification Agreement (this “Agreement”) is dated as of [______ __, 20__], and is between Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), and [______] (“Indemnitee”).
Edgewise Therapeutics, Inc. Common stock SALES AGREEMENTCommon Stock Sales Agreement • April 1st, 2022 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 1st, 2022 Company Industry JurisdictionEdgewise Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
March 3, 2021Confirmatory Employment Letter • March 5th, 2021 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • Colorado
Contract Type FiledMarch 5th, 2021 Company Industry Jurisdiction
LEASE FOR PREMISES LOCATED AT JENNIE SMOLY CARUTHERS BIOTECHNOLOGY BUILDING UNIVERSITY OF COLORADO BOULDER 3415 COLORADO AVENUE, BOULDER, COLORADO 80309 BY AND BETWEEN EDGEWISE THERAPEUTICS, INC., A DELAWARE CORPORATION AS TENANT AND THE REGENTS OF...Lease Agreement • March 5th, 2021 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • Colorado
Contract Type FiledMarch 5th, 2021 Company Industry JurisdictionTHIS LEASE AGREEMENT (“Lease”) is made by and between Landlord and Tenant hereinafter named. In consideration of the respective covenants, obligations, and agreements of the parties set forth herein, the legal sufficiency of which is acknowledged by each of the undersigned, Landlord and Tenant agree as follows:
Edgewise Therapeutics, Inc. Common stock SALES AGREEMENTCommon Stock Sales Agreement • May 10th, 2024 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 10th, 2024 Company Industry JurisdictionEdgewise Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (“Leerink Partners”), as follows:
RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • May 11th, 2023 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • Colorado
Contract Type FiledMay 11th, 2023 Company Industry JurisdictionUnless otherwise defined herein, the terms defined in the Edgewise Therapeutics, Inc. 2021 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement which includes the Notice of Restricted Stock Unit Grant (the “Notice of Grant”), the Terms and Conditions of Restricted Stock Unit Grant, attached hereto as Exhibit A, and all other exhibits, appendices, and addenda attached hereto (the “Award Agreement”).
EDGEWISE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • December 18th, 2020 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 18th, 2020 Company Industry JurisdictionThis Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of December 3, 2020 (the “Effective Date”), by and among Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons and entities listed on Exhibit A hereto (each, an “Investor” and collectively, the “Investors”).